Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer’s Disease
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-220769 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Neal R Swerdlow und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Memantine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: RRD VA, NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background
The uncompetitive NMDA antagonist, memantine (MEM), enhances prepulse inhibition of startle (PPI) across species. MEM is used to treat Alzheimer’s disease (AD); conceivably, its acute impact on PPI might be used to predict a patient’s sensitivity to MEM’s therapeutic effects.
Objective
To begin to test this possibility, we studied MEM effects on PPI and related measures in AD patients.
Methods
18 carefully screened individuals with AD (mean age = 72.8 y; M:F=9 : 9) completed double-blind order-balanced testing with MEM (placebo versus 20 mg), assessing acoustic startle magnitude, habituation, PPI, and latency.
Results
Fifteen out of 18 participants exhibited reliable startle responses. MEM did not significantly impact startle magnitude or habituation. Compared to placebo responses, PPI was significantly increased after MEM (p < 0.04; d = 0.40); this comparison reached a large effect size for the 60 ms interval (d = 0.62), where maximal MEM effects on PPI were previously detected. Prepulses reduced peak startle latency (“latency facilitation”) and this effect was amplified after MEM (p = 0.03; d = 0.41; for 60 ms intervals, d = 0.69). No effects of MEM were detected on cognition, nor were MEM effects on startle associated with cognitive or clinical measures.
Conclusion
MEM enhances prepulse effects on startle magnitude and latency in AD; these changes in PPI and latency facilitation with MEM suggest that these measures can be used to detect an AD patient’s neural sensitivity to acute MEM challenge. Studies in progress will determine whether such a “biomarker” measured at the outset on treatment can predict sensitivity to MEM’s therapeutic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
- VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
- Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, CA, USA.
- Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Förderung
- RRD VA
- NIA NIH HHS
Zitieren
APA
Swerdlow, N. R., Joshi, Y. B., Sprock, J., Talledo, J., Molina, J. L., Delano-Wood, L., Iwanaga, D., Kotz, J. E., Huege, S., Léger, G. C., & Light, G. A. (2023). Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer’s Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-220769
Vancouver
Swerdlow NR, Joshi YB, Sprock J, Talledo J, Molina JL, Delano-Wood L, et al. Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer’s Disease. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-220769
BibTeX
@article{Swerdlow2023,
author = {Swerdlow, Neal R and Joshi, Yash B and Sprock, Joyce and Talledo, Jo and Molina, Juan L and Delano-Wood, Lisa and Iwanaga, Dylan and Kotz, Juliana E and Huege, Steven and Léger, Gabriel C and Light, Gregory A},
title = {Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer’s Disease},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-220769}
}
EUVIMED